Abstract
A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
Keywords: Docosahexaenoic acid, eicosapentaenoic acid, omega-3, psychiatric disorders, trials.
Current Drug Discovery Technologies
Title:Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Volume: 10 Issue: 3
Author(s): Pierluigi Politi, Matteo Rocchetti, Enzo Emanuele, Mariangela Rondanelli and Francesco Barale
Affiliation:
Keywords: Docosahexaenoic acid, eicosapentaenoic acid, omega-3, psychiatric disorders, trials.
Abstract: A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
Export Options
About this article
Cite this article as:
Politi Pierluigi, Rocchetti Matteo, Emanuele Enzo, Rondanelli Mariangela and Barale Francesco, Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature, Current Drug Discovery Technologies 2013; 10 (3) . https://dx.doi.org/10.2174/1570163811310030007
DOI https://dx.doi.org/10.2174/1570163811310030007 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clozapine Safety, 40 Years Later
Current Drug Safety Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Nitric Oxide Production during Cerebral Ischemia and Reperfusion in eNOS- and nNOS-Knockout Mice
Current Neurovascular Research Incomplete Coverage of Candidate Genes: A Poorly Considered Bias
Current Genomics Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism
Current Pharmaceutical Design Amyloidogenesis of Natively Unfolded Proteins
Current Alzheimer Research Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry Drug Therapy for Patients with Eating Disorders
Current Drug Targets - CNS & Neurological Disorders Non-Analgesic Effects of Opioids: Opioid-induced Nausea and Vomiting: Mechanisms and Strategies for their Limitation
Current Pharmaceutical Design Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology